A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

Exclusion Criteria

• •Predominant pattern of pustular, erythrodermic, or guttate forms of psoriasis
• •History of drug-induced psoriasis
• •Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study
• •Received systemic non-biologic psoriasis therapy or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment
• •Concurrent or recent use of any biologic agent
• •Have participated in any study with ixekizumab
• •Received a live vaccination within 12 weeks prior to enrollment
• •Serious disorder or illness other than psoriasis
• •Ongoing or serious infection within the last 12 weeks or evidence of tuberculosis
• •Major surgery within 8 weeks of baseline, or will require surgery during the study
• •Breastfeeding or nursing (lactating) women